DT2216 is primarily utilized in the field of medical research, particularly in the development of targeted cancer therapies. It functions as a bispecific molecule designed to engage immune cells, such as T cells, to specifically attack cancer cells. This approach enhances the immune system's ability to recognize and destroy malignant cells while minimizing damage to healthy tissues. Its application is being explored in preclinical and clinical studies to evaluate its efficacy and safety in treating various types of cancers, including hematologic malignancies and solid tumors. Additionally, DT2216 is being investigated for its potential to improve the outcomes of immunotherapies by overcoming resistance mechanisms often observed in cancer treatment.